{"id":"NCT03277313","sponsor":"Baxalta now part of Shire","briefTitle":"Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects","officialTitle":"Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-25","primaryCompletion":"2022-07-20","completion":"2022-07-20","firstPosted":"2017-09-11","resultsPosted":"2023-10-23","lastUpdate":"2023-10-23"},"enrollment":44,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Primary Immunodeficiency Diseases (PID)"],"interventions":[{"type":"BIOLOGICAL","name":"HYQVIA","otherNames":["IGI 10% with rHuPH20"]}],"arms":[{"label":"Epoch 1","type":"EXPERIMENTAL"},{"label":"Epoch 2","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to acquire additional data on efficacy, safety, tolerability, immunogenicity, pharmacokinetic (PK) and other parameters of HYQVIA in pediatric (age â‰¥ 2 to \\<16 years) participants with primary immunodeficiency disease (PIDD).","primaryOutcome":{"measure":"Rate Represented as Mean Number of Acute Serious Bacterial Infections (ASBI) Per Participant-year","timeFrame":"From first dose of study drug up to end of Study Epoch 2 (up to approximately 37.2 months)","effectByArm":[{"arm":"Epoch 1 + Epoch 2","deltaMin":0.04,"sd":0.027}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b5fc54db2bf003ab45c6c"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":44},"commonTop":["Infusion site pain","Headache","Sinusitis","Infusion site erythema","Infusion site pruritus"]}}